BetterLife Pharma Inc.BETR.CN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · CSE · Canada · blifepharma.com
BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing BETR-001 to treat various neurological disorders. BETR-001 is a non-hallucinogenic, non-controlled LSD derivative in preclinical and IND-enabling studies.
Key ratios
ROA
-500.6%TTM
2026
-508.2%2025
-1074.4%2024
-1004.4%
Recent news
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
BetterLife Pharma Inc. Announces Pricing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
Track BETR.CN in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer